{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:01:45Z","timestamp":1789524105893,"version":"build-2803163510"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>A disabling peripheral nervous system disorder, Guillain-Barr\u00e9 syndrome (GBS), has very limited treatment options. However, some patients have poor outcomes even after receiving treatment. This study aimed to compare the efficacy of efgartigimod versus intravenous immunoglobulin (IVIG) for treating GBS with disability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed data from GBS patients who were unable to walk independently and were admitted between January 1, 2023, and February 28, 2025. Our primary outcome was the proportion of patients able to walk independently at week 4 and able to run at week 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After including 34 patients in the study, we divided them into two groups: 12 in the efgartigimod group and 22 in the IVIG group. Patients on efgartigimod displayed numerically better short-term (100% vs. 64%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.03) and long-term (100% vs. 55%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.006) outcomes than those treated with IVIG.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Efgartigimod showed favorable safety and clinical efficacy for treating GBS with disability in this single-center retrospective study, with notable clinical improvement observed in patients with ophthalmoplegia and respiratory insufficiency. Larger prospective studies are needed to validate these preliminary findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1734853","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:37:00Z","timestamp":1776145020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efgartigimod as a potential alternative to intravenous immunoglobulin in Guillain-Barr\u00e9 syndrome: a retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Changyue","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Neurology, Fourth Ward, Linyi People\u2019s Hospital","place":["Linyi, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fourth Ward, Linyi People\u2019s Hospital","place":["Linyi, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fourth Ward, Linyi People\u2019s Hospital","place":["Linyi, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiyong","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fourth Ward, Linyi People\u2019s Hospital","place":["Linyi, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fourth Ward, Linyi People\u2019s Hospital","place":["Linyi, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faying","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fourth Ward, Linyi People\u2019s Hospital","place":["Linyi, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain\u2013Barr\u00e9 syndrome: Pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"Van Den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001798.pub3","article-title":"Plasma exchange for Guillain-Barr\u00e9 syndrome","volume":"2017","author":"Chevret","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01253-4","article-title":"Immunoglobulin and monoclonal antibody therapies in Guillain-Barr\u00e9 syndrome","volume":"19","author":"Rajabally","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): A misnomer","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1730-x","article-title":"Modulation of IgG\u2013FcRn interactions to overcome antibody-mediated inhibition of nerve regeneration","volume":"134","author":"Zhang","year":"2017","journal-title":"Acta Neuropathol (Berl)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251314746","article-title":"Sequential administration of efgartigimod shortened the course of Guillain\u2013Barr\u00e9 syndrome: A case series","volume":"18","author":"Chen","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040700","article-title":"Resolution of acute motor axonal neuropathy in a patient after treatment with efgartigimod: A case report","volume":"103","author":"Zhou","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12321-4","article-title":"Efgartigimod in the treatment of Guillain\u2013Barr\u00e9 syndrome","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome","volume":"27","author":"Asbury","year":"1990","journal-title":"Ann Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2013Barr\u00e9 syndrome","volume":"326","author":"Van Der Mech\u00e9","year":"1992","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16073","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome","volume":"30","author":"van Doorn","year":"2023","journal-title":"Eur J Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.4.1110","article-title":"The spectrum of antecedent infections in Guillain-Barr\u00e9 syndrome: A case-control study","volume":"51","author":"Jacobs","year":"1998","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1212\/01.wnl.0000234967.76960.3c","article-title":"Acute motor conduction block neuropathy followed by axonal degeneration and poor recovery","volume":"67","author":"Uncini","year":"2006","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq260","article-title":"Conduction block in acute motor axonal neuropathy","volume":"133","author":"Kokubun","year":"2010","journal-title":"Brain"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2215153","article-title":"Progress in Guillain\u2013Barr\u00e9 syndrome immunotherapy\u2014A narrative review of new strategies in recent years","volume":"19","author":"Yao","year":"2023","journal-title":"Hum Vaccines Immunother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.72.5.680","article-title":"Plasmapheresis and Miller Fisher syndrome: Analysis of 50 consecutive cases","volume":"72","author":"Mori","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000258673.31824.61","article-title":"Intravenous immunoglobulin therapy for Miller Fisher syndrome","volume":"68","author":"Mori","year":"2007","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1056\/NEJM195607122550201","article-title":"An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia)","volume":"255","author":"Fisher","year":"1956","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1840355","article-title":"Mechanical ventilation in Guillain\u2013Barr\u00e9 syndrome","volume":"16","author":"Shang","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcv190","article-title":"Outcome of Guillain\u2013Barre syndrome patients with respiratory paralysis","volume":"109","author":"Kalita","year":"2016","journal-title":"QJM"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000013139","article-title":"Predicting outcome in Guillain-Barr\u00e9 syndrome: International validation of the modified Erasmus GBS outcome score","volume":"98","author":"Doets","year":"2022","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy232","article-title":"Regional variation of Guillain-Barr\u00e9 syndrome","volume":"141","author":"Doets","year":"2018","journal-title":"Brain"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1038411","article-title":"Sex differences in Guillain Barr\u00e9 syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis","volume":"13","author":"McCombe","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-329937","article-title":"Modified Erasmus GBS respiratory insufficiency score: A simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barr\u00e9 syndrome","volume":"94","author":"Luijten","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1734853\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:37:01Z","timestamp":1776145021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1734853\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1734853"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1734853","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"1734853"}}